Skip to main content

Market Overview

ICAD Focuses On Areas Of High Unmet Need In Cancer Detection, BTIG Says

ICAD Focuses On Areas Of High Unmet Need In Cancer Detection, BTIG Says

ICAD Inc (NASDAQ: ICAD) is poised to benefit in the long term from its AI-driven cancer detection tools and electronic brachytherapy product, according to BTIG.

The iCAD Analyst: Marie Thibault initiated coverage of iCAD with a Buy rating and a price target of $25.

The iCAD Thesis: The company’s two business segments — ProFound AI and Xoft eBx — are focused on “expanding into areas of high unmet need,” Thibault said in the initiation note.

ICAD was the first to market an AI-powered detection solution for digital breast tomosynthesis. Its market leadership and large installed base give the company “a strong position for growth,” she added.

“We expect this fast pace of adoption to speed up further as the pandemic wanes and as the full launch of ProFound AI Risk for DBT kicks off this year,” the analyst further wrote.

“Xoft has broad regulatory clearances but is also being studied in specific cancer types, most notably glioblastoma, where its use has shown promising early clinical results and it is being evaluated in a larger trial now,” Thibault said.

ICAD Price Action: Shares of iCAD are down 1.91% to $18.98 at the time of publication Tuesday.

(Photo by National Cancer Institute on Unsplash)

Latest Ratings for ICAD

Apr 2021GuggenheimInitiates Coverage OnBuy
Mar 2021BTIGInitiates Coverage OnBuy
Feb 2021OppenheimerInitiates Coverage OnOutperform

View More Analyst Ratings for ICAD
View the Latest Analyst Ratings


Related Articles (ICAD)

View Comments and Join the Discussion!

Posted-In: AIAnalyst Color Biotech Price Target Initiation Small Cap Analyst Ratings General

Latest Ratings

PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at